NERV Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Minerva Neurosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.85 |
| 52 Week High | US$9.40 |
| 52 Week Low | US$1.80 |
| Beta | 0.11 |
| 1 Month Change | -17.04% |
| 3 Month Change | -16.29% |
| 1 Year Change | -78.98% |
| 3 Year Change | -67.09% |
| 5 Year Change | -96.85% |
| Change since IPO | -96.18% |
Recent News & Updates
Recent updates
Minerva says FDA declined to accept marketing application for schizophrenia drug
Oct 17Minerva Neurosciences: Biotech On The Move
Aug 29Minerva stock rises on filing for FDA approval of schizophrenia therapy
Aug 22We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely
Jun 22
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?
Jan 26Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
Oct 02Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares
Mar 03What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition
Jan 27We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate
Dec 23
A Potential Trade Arises On Minerva
Dec 09A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns
Nov 18Minerva Neurosciences EPS beats by $0.03
Nov 02Shareholder Returns
| NERV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.6% | 3.7% | 1.2% |
| 1Y | -79.0% | -1.0% | 23.7% |
Return vs Industry: NERV underperformed the US Biotechs industry which returned -1% over the past year.
Return vs Market: NERV underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| NERV volatility | |
|---|---|
| NERV Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NERV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NERV's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 9 | Remy Luthringer | www.minervaneurosciences.com |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.
Minerva Neurosciences, Inc. Fundamentals Summary
| NERV fundamental statistics | |
|---|---|
| Market cap | US$13.64m |
| Earnings (TTM) | -US$3.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.9x
P/E RatioIs NERV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NERV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$12.40m |
| Gross Profit | -US$12.40m |
| Other Expenses | -US$9.09m |
| Earnings | -US$3.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -276.9% |
How did NERV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 11:23 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Minerva Neurosciences, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Thomas Shrader | BTIG |
| Douglas Tsao | H.C. Wainwright & Co. |